SciSparc Stocks Surge 50% In Pre-Market After N2OFF Approves MitoCareX Acquisition

SciSparc Ltd. (SPRC) shares are up over 58% in premarket trading after N2OFF Inc. (NITO) stockholders approved the acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd. The transaction, anticipated to close in October, involves SciSparc receiving $0.7 million in cash, while the sellers will collectively obtain 40% of N2OFF's fully diluted capital stock and up to $1.6 million from future N2OFF financing proceeds. N2OFF will also commit $1 million in cash and two years of financial support to MitoCareX, a cancer therapeutics developer, marking a strategic expansion into a market projected to reach $344.1 billion by 2031.

Analysis

The approval by N2OFF Inc. (NITO) stockholders for the acquisition of SciSparc Ltd.'s (SPRC) subsidiary, MitoCareX Bio Ltd., represents a significant strategic milestone for both entities, as validated by the market's strong positive reaction. For SciSparc, the transaction structure is multifaceted, providing an immediate $0.7 million cash infusion, a substantial equity position equivalent to 40% of N2OFF's fully diluted capital (shared with other sellers), and a future revenue stream of up to $1.6 million contingent on N2OFF's financing. This deal effectively monetizes SciSparc's cancer-focused subsidiary while retaining significant upside through the N2OFF stake, allowing SPRC to de-risk its own operations from MitoCareX's R&D expenses. For N2OFF, the acquisition marks a strategic pivot into the high-growth cancer therapeutics market, which is projected to expand to $344.1 billion by 2031. N2OFF's commitment to invest $1 million in cash and provide two years of financial support underscores its intent to actively develop the MitoCareX platform. The premarket surge of over 58% in SPRC shares indicates investors perceive this as a significant value-unlocking event, while NITO's more moderate 4.96% gain reflects a positive outlook tempered by the financial commitments and execution risks of entering the competitive biotech space.

Key Decisions for Investors

• Investors in SciSparc (SPRC) should recognize this divestiture as a de-risking event that provides immediate cash and retains exposure to MitoCareX's success through a significant equity holding in N2OFF.
• Potential and current N2OFF (NITO) investors must now evaluate the company as a player in the oncology space, weighing the high-growth potential of MitoCareX's platform against the execution risk and capital required to advance its pre-clinical assets.
• Given the transaction is expected to close in the first half of October, both SPRC and NITO share prices may exhibit volatility around this period, and investors should monitor for any announcements regarding deal completion or changes to the terms.
• The ongoing performance of N2OFF, particularly its ability to secure financing post-acquisition, should be tracked as a key catalyst, as this will directly influence both the development of MitoCareX and the realization of the $1.6 million in additional payments for SciSparc.